HK Stock Market Move | KEYMED BIO-B(02162) increased by over 4%, institutions are optimistic about the global value of CM512, and sales of Sipochibai monoclonal antibodies are expected to increase rapidly next year.

KEYMED BIO-B (02162) rose more than 4%, rising 4.08% to HKD 59.95 as of the report, with a turnover of HKD 312.82 million. In terms of news, recently, KEYMED BIO-B announced that the company's independently developed global first long-acting TSLP x IL-13 dual inhibitor CM512 has achieved all research endpoints in Phase I clinical trials for the treatment of moderate to severe atopic dermatitis (AD) in adults. Huatai pointed out that the global long-acting self-immune track is hot right now, with APOGEE's market value growing more than 75% in the past two months, currently valued at USD 4.3 billion. In early November, the company disclosed early clinical data for CM512, which showed that EASI-90 for the treatment of AD with CM512 was significantly better than APOGEE's core asset APG777 in a non-head-to-head comparison. Additionally, CM512 demonstrated excellent safety performance and a dosing frequency similar to APG777, highlighting the global value of CM512. The report also mentioned that Dupilumab is being discussed in several countries for the treatment of AD, CRSwNP, and SAR. Considering the expected new indications for COPD, asthma, and PN under the EMA's simplified rules, along with the impact of high reductions in medical insurance negotiations last year and cost pressures, it is predicted that the potential for price reductions for Dupilumab this year may be limited. The company's commercial sales team is steadily expanding, expected to reach around 400 by the end of the year, and actively promoting hospital access and coverage. Prioritizing AD in key hospitals as the core focus for breakthrough scenarios, sales of Dupilumab are expected to see rapid growth by 2026.